In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.
16hOpinion
No one has ever known so much about healthy eating and been less successful at following her own advice.
Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.
Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback